| | | | | | |
| | (vi) | | any extraordinary, unusual or non-recurring charges, expenses or losses (including, without limitation, losses on asset sales and |
| | | | litigation fees, costs, settlements, judgments and expenses), plus | | $ |
| | | |
| | (vii) | | losses on Investments, plus | | $ |
| | |
| | (viii) | | any impairment charges and expense (including all unit-specific, brand, goodwill or other intangible impairment charges and |
| | | | expense), plus | | $ |
| | |
| | (ix) | | any expenses, fees, charges, or losses related to any equity offering, permitted Investment, Restricted Payment, |
| | | | acquisition, disposition, recapitalization, merger, or the incurrence of Indebtedness permitted to be incurred by |
| | | | this Agreement (including any refinancing, exchange or repayment thereof) (whether or not successful and |
| | | | including any such transaction consummated prior to the Closing Date), including (A) such fees, expenses, or |
| | | | charges related to the incurrence of the Loans under the Credit Agreement and all Transaction Costs (including |
| | | | the fees, expenses and disbursements of appraisers, consultants, advisors, brokers, accountants and counsel), (B) |
| | | | such fees, expenses, or charges related to the execution of the Loan Documents and any other credit facilities or |
| | | | debt issuances, and (C) any amendment, restatement, waiver or other modification of any Loan Document, | | the |
| | | | Loans under the Credit Agreement or other Indebtedness (or the documentation related thereto), plus | | $ |
| | | |
| | (x) | | non-cash compensation charges or other expenses or charges, plus | | $ |
| | |
| | (xi) | | any other non-cash charges, including any write offs, write downs, expenses, losses (provided that if any such |
| | | | non-cash charges represent an accrual or reserve for potential cash items in any future Test Period, the cash |
| | | | payment in respect thereof in such future Test Period shall be deducted from Consolidated EBITDA to such |
| | | | extent, and excluding amortization of a prepaid cash item that was paid in a prior Test Period), plus | | $ |
| | |
| | (xii) | | pro forma adjustments, including pro forma “run-rate” cost savings, operating expense reductions, operational |
| | | | improvements and other synergies related to (A) the Transactions that are reasonably identifiable and that are |
| | | | projected by the Borrower in good faith to result from actions either taken or with respect to which substantial |
| | | | steps have been take or are expected to be taken in the good faith determination of the Borrower within 12 months |
| | | | of the Closing Date and (B) any acquisition (including the commencement of activities constituting a business), |
| | | | disposition (including the termination or discontinuance of activities constituting a business) or other specified |
| | | | investment or transaction, or related to any restructuring initiative, cost savings initiative or other initiative that |
| | | | are reasonably identifiable and projected by the Borrower in good faith to result from actions that have been taken |
| | | | or with respect to which steps have been taken or are expected to be taken (in the good faith determination of the |
| | | | Borrower) within 12 months of the determination to take such action, in each case, net of the amount of actual |
| | | | benefits realized prior to or during such Test Period from such actions (which cost savings, operating expense |
| | | | reductions, operating enhancements and synergies shall be calculated on a Pro Forma Basis as though such cost |
| | | | savings, operating expense reductions, operating enhancements or synergies had been realized on the first day of |
| | | | such Test Period); provided that the aggregate amount added back pursuant to this clause (xii), together with the |
| | | | aggregate amount added back pursuant to clause (iv) above, shall not cumulatively exceed 20% of Consolidated |
| | | | EBITDA for any Test Period (with such calculation being made before giving | | |
| | | | effect to any increase pursuant to this clause (xii)), plus | | $ |
| | |
| | (xiii) | | (x) all gains and charges as a result of, or in connection with, sales, dispositions or abandonments of assets |
| | | | outside the ordinary course of business (including, without limitation, asset retirement costs) and (y) charges |
| | | | from disposed, abandoned, divested and/or discontinued assets, Properties or operations and/or discontinued |
| | | | assets, Properties and operations (other than, at the option of the Borrower, assets or Properties or operations | | |
| | | | pending the divestiture or termination thereof), plus | | $ |
| |
| | (xiv) earn-out obligations incurred in connection with any Material Acquisition or other Investment and paid or |
| | | | accrued during the applicable Test Period and any related expenses, plus | | $ |
| | |
| | (xv) | | (x) any expenses and charges that are reimbursable by a third party pursuant to indemnification or other similar |
| | | | provisions and actually reimbursed and (y) expenses and reimbursements with respect to liability or casualty | | |
| | | | events or business interruption, to the extent covered by insurance and actually reimbursed, or, in each case of |
| | | | clauses (x) and (y) of this clause (xv), if not actually reimbursed, so long as the Borrower has a good faith |
| | | | expectation that such amounts will be received within the next four fiscal quarters (with a deduction for any |
| | | | amount so added back to the extent not so reimbursed within the next four fiscal quarters), plus | | $ |
| |
| | (xvi) any effects of adjustments resulting from the application of purchase accounting, purchase price accounting |
| | | | (including any step-up in inventory and loss of profit on the acquired inventory), plus | | $ |
| | |
| | (xvii) | | other items recorded under “other income expense” in the Borrower financial statements prepared in accordance |
| | | | with GAAP; provided that the aggregate amount added back pursuant to this clause (xvii) shall not exceed 5% of |
| | | | Consolidated EBITDA for any Test Period (with such calculation being made before giving effect to any |
| | | | increase pursuant to this clause (xvii)), | | $ |